BDX May 2024 250.000 call
| Previous close | 0.2400 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 2.5000 |
| Strike | 250.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 307 |
ZacksBD's (BDX) FDA-Approved Test to Offer Wider Testing Access
BD's (BDX) receipt of the FDA's clearance for the use of self-collected vaginal specimens for HPV testing is likely to improve screening access to a wider female population.
PR NewswireWomen in U.S. Can Now Collect Their Own Sample for Cervical Cancer Screening
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) approval for the use of self-collected vaginal specimens for human papillomavirus (HPV) testing when cervical specimens cannot otherwise be obtained. The approval allows women to self-collect vaginal specimens for HPV testing in a health care setting, which could include non-traditional locations such as a retail pharmacy or mobile clinic.
Insider Monkey11 Best Recession Dividend Stocks To Buy
In this article, we discuss 11 best recession dividend stocks to buy. You can skip our detailed analysis of dividend stocks and their past performance during recessionary periods, and go directly to read 5 Best Recession Dividend Stocks To Buy. Several financial analysts, previously forecasting a recession in the US at the end of 2022, […]
